Sugi Predict

Sugi Predict / Targets / DDR1

DDR1

Epithelial discoidin domain-containing receptor 1 · Q08345 · DDR1 on Sugi Atlas →

76,530 patent compounds predicted against DDR1, 49,061 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL123078 SCHEMBL123078 0.39 6/20
SCHEMBL40153 SCHEMBL40153 0.48 4/20
SCHEMBL45407 SCHEMBL45407 0.40 4/20
SCHEMBL59277 SCHEMBL59277 0.39 4/20
SCHEMBL46800 SCHEMBL46800 0.41 3/20
Sorafenib Sorafenib (SCHEMBL8218) 1.00 2/20
Dasatinib Anhydrous Dasatinib Anhydrous (SCHEMBL8226) 1.00 2/20
Sorafenib Sorafenib (SCHEMBL162935) 0.81 2/20
SCHEMBL170976 SCHEMBL170976 0.80 2/20
Sorafenib Sorafenib (SCHEMBL19322) 0.80 2/20
SCHEMBL170966 SCHEMBL170966 0.74 2/20
SCHEMBL169257 SCHEMBL169257 0.68 2/20
SCHEMBL141040 SCHEMBL141040 0.67 2/20
SCHEMBL170956 SCHEMBL170956 0.65 2/20
SCHEMBL169157 SCHEMBL169157 0.65 2/20
SCHEMBL171188 SCHEMBL171188 0.61 2/20
SCHEMBL69095 SCHEMBL69095 0.60 2/20
SCHEMBL140837 SCHEMBL140837 0.59 2/20
SCHEMBL171026 SCHEMBL171026 0.59 2/20
SCHEMBL171051 SCHEMBL171051 0.59 2/20

Clinical trials — most relevant to DDR1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Phase 3 Study of Sitravatinib Plus Nivolumab vs Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer PHASE3COMPLETED
Cisplatin to Patients With Pancreatic Cancer and Homologous Recombination Deficiency PHASE2/PHASE3RECRUITING
Pembrolizumab With Sitravatinib in Recurrent Endometrial Cancer and Other Solid Tumors With Deficient Mismatch Repair System PHASE2WITHDRAWN
Study of ART6043 in Advanced/Metastatic Solid Tumors Patients (POLKA) PHASE1/PHASE2RECRUITING
Avelumab and M6620 for the Treatment of DDR Deficient Metastatic or Unresectable Solid Tumors PHASE1/PHASE2ACTIVE_NOT_RECRUITING
I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers PHASE1/PHASE2NOT_YET_RECRUITING
Pembrolizumab Plus Enfortumab Vedotin in Collecting Duct and Renal Medullary Carcinoma PHASE2RECRUITING
Olaparib and Durvalumab (MEDI4736) in Patients with Metastatic Pancreatic Cancer and DNA Damage Repair Genes Alterations PHASE2ACTIVE_NOT_RECRUITING
Rechallenge With Panitumumab Driven by RAS Dynamic of Resistance PHASE2COMPLETED
EGF Ointment for Erlotinib Skin Lesion PHASE2COMPLETED
Phase II Study of Vandetanib in Individuals With Kidney Cancer PHASE2COMPLETED
Testing Dasatinib as a Potential Targeted Treatment in Cancers With DDR2 Genetic Changes (MATCH-Subprotocol X) PHASE2WITHDRAWN
Trial of Olaparib in Patients With Metastatic Urothelial Cancer Harboring DNA Damage Response Gene Alterations PHASE2COMPLETED
Phase 1/1b Study of MGCD516 in Patients With Advanced Cancer PHASE1COMPLETED
First-in-human Study of ATR Inhibitor BAY1895344 in Patients With Advanced Solid Tumors and Lymphomas PHASE1COMPLETED
Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom Trial PHASE1RECRUITING
Dacomitinib Plus Radiotherapy, With and Without Cisplatin in Patients With Squamous Cell Carcinoma of the Head and Neck PHASE1COMPLETED
Study of TARCEVA (Erlotinib) as Adjuvant Treatment for Locally Advanced Head and Neck Squamous Cell Carcinoma PHASE1COMPLETED
Erlotinib and Surgery in Treating Patients With Head and Neck Cancer That Can Be Removed by Surgery EARLY_PHASE1COMPLETED
Clinical Application of 68Ga-1A12 PET in Fibrosis-related Diseases nanNOT_YET_RECRUITING
Clinical Study on the Application of PET Probes Targeting DDR2 in the Diagnosis of Interstitial Lung Disease With Cognitive Impairment nanNOT_YET_RECRUITING
Prognostic Biomarkers in Patients With Urothelial Carcinoma nanCOMPLETED
Prospective Monocentric Clinical-biological Database nanRECRUITING
Investigation of Methylation of EGFR in the Response of the Cetuximab in Metastatic Colorectal Cancer Patients nanCOMPLETED
Prognostic Value of Her2neu and EGFR in Primary Ovarian High Grade Serous Carcinoma. nanCOMPLETED
The Activation of Hippo Pathway in Nasal Polyps nanUNKNOWN
Biomarkers in Tumor Tissue Samples From Younger Patients With Rhabdomyosarcoma nanCOMPLETED
K-RAS Oncogene Mutation in Patients With Advanced Non-Small Cell Lung Cancer Associated With Exposure to Wood Smoke and Tobacco Smoking: Therapeutic Implications nanCOMPLETED
Novel Biomarkers in the Neoplastic Progression of Barrett's Esophagus nanACTIVE_NOT_RECRUITING
Investigate eNAMPT in Multiple Myeloma Biology and Establish Its Role in Disease Progression nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a DDR1 binder may also engage these)

ProteinNameSimilarity
Q63474 — 1.000 Q63474 →
Q03146 — 1.000 Q03146 →
Q7YR43 — 1.000 Q7YR43 →
Q8BYG9 — 0.990 Q8BYG9 →
P0C0K6 — 0.989 P0C0K6 →
EPHB4 Ephrin type-B receptor 4 0.989 landscape →
O09127 — 0.989 O09127 →
P0C0K7 — 0.988 P0C0K7 →
INSRR Insulin receptor-related protein 0.986 landscape →
Q99ML2 — 0.986 Q99ML2 →
O08644 — 0.985 O08644 →
P52785 — 0.985 P52785 →
P51840 — 0.985 P51840 →
JAK3 Tyrosine-protein kinase JAK3 0.985 landscape →
Q5JZY3 — 0.984 Q5JZY3 →
P35546 — 0.984 P35546 →
CSF1R Macrophage colony-stimulating factor 1 receptor 0.984 landscape →
Q06805 — 0.984 Q06805 →
EPHB6 Ephrin type-B receptor 6 0.983 landscape →
P51839 — 0.983 P51839 →
TNK1 Non-receptor tyrosine-protein kinase TNK1 0.983 landscape →
P55203 — 0.983 P55203 →
Q9WTL4 — 0.983 Q9WTL4 →
Q00495 — 0.982 Q00495 →
P13369 — 0.982 P13369 →
EPHA1 Ephrin type-A receptor 1 0.982 landscape →
P54761 — 0.982 P54761 →
P54754 — 0.982 P54754 →
Q60750 — 0.981 Q60750 →
TIE1 Tyrosine-protein kinase receptor Tie-1 0.981 landscape →